Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma. [electronic resource]
Producer: 20191008Description: 3146-3159 p. digitalISSN:- 1097-0215
- Animals
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Drug Screening Assays, Antitumor
- Drug Synergism
- Humans
- Mice
- Neuroblastoma -- drug therapy
- Prodrugs -- pharmacokinetics
- Proto-Oncogene Proteins c-mdm2 -- antagonists & inhibitors
- Pyrrolidines -- pharmacokinetics
- Random Allocation
- Temozolomide -- administration & dosage
- Tumor Suppressor Protein p53 -- genetics
- Xenograft Model Antitumor Assays
- para-Aminobenzoates -- pharmacokinetics
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.